New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.
TipRanks on MSN
Sanofi’s New COPD Treatment Study: A Potential Game-Changer?
Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...
After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended the grant of ...
Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...
The Fort St. John Hospital Foundation has purchased a body plethysmograph, a vital piece of equipment for the respiratory ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.
The respiratory medical community is moving toward shared decision-making in self-managing chronic respiratory disease, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback